Our group is proud to announce that we have been awarded the Division of Radiology and Nuclear Medicine (KRN) Best Article of the Year 2024/2025 for our outstanding work on the First-in-Human Phase 0 Study of AB001, a Prostate-Specific Membrane Antigen-Targeted ²¹²Pb Radioligand in Patients with Metastatic Castration-Resistant Prostate Cancer. The award was presented by division head Paulina Due-Tønnessen on Wednesday October 29th, followed by a presentation by senior author Caroline. This paper was a result of a fruitful collaboration between several groups at OUS, and the trial itself was sponsored by ARTBIO (PI Kjetil Berner from the Department of Oncology, OUS). Congratulations to our group members Eivor Hernes, Monika Kvassheim, Simen Rykkje Grønningsæter and Caroline Stokke, as well as the whole team on this well-deserved recognition!

Our research group is pleased to announce that we have had results from a phase 0-trial on AB001, a novel PSMA-targeted radioligand labeled with the α-emitter 212Pb, accepted for publication in the Journal of Nuclear Medicine. The study explores the use of γ-camera imaging to assess biodistribution and uptake of AB001 in patients with metastatic castration-resistant prostate cancer (mCRPC).

The study was conducted at Oslo University Hospital, and sponsored by ARTBIO. The publication was a result of an excellent multidisiplinary collaboration, and especially the joint first authors Kjetil Berner (Department of Oncology) and Eivor Hernes (Department of Nuclear Medicine), together with Monika Kvassheim and senior author Caroline Stokke (our group) played key roles. Group members Simen Rykkje Grønningsæter and Lars Tore Gyland Mikalsen also gave valuable contributions. The work showed that AB001 can be safely administered and imaged at a microdose of only 10 MBq, and successfully demonstrated metastatic targeting. The findings offer valuable insights into the biodistribution and clearance of 212Pb-labeled radioligands, paving the way for further clinical development in targeted alpha therapy.